Actively Recruiting
Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
Led by University of California, San Francisco · Updated on 2026-01-26
2500
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
U
University of Stellenbosch
Collaborating Sponsor
AI-Summary
What this Trial Is About
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
CONDITIONS
Official Title
Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Active rifampin-resistant tuberculosis diagnosed at a study facility during the study period
- Positive Mycobacterium tuberculosis culture, smear, or specimen derivative (e.g., GenoLyse remnant, Xpert cartridge extract)
You will not qualify if you...
- Patient expects to relocate or move residence outside of the study region
- Patient does not agree to participate in the study
- Participants later found to have rifamycin susceptibility on at least two additional tests (e.g., phenotypic DST, LPA, or sequencing) will be excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
South African National Health Laboratory Service
Cape Town, South Africa
Actively Recruiting
Research Team
J
John Z Metcalfe, MD, PhD
CONTACT
R
Rob Warren, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here